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Abstract
Sphingosine-1-phosphate (S1P), a sphingolipid metabolite that is produced inside the cells, regulates a variety of
physiological and pathological responses via S1P receptors (S1P1–5). Signal transduction between cells consists of three
steps; the synthesis of signaling molecules, their export to the extracellular space and their recognition by receptors. An S1P
concentration gradient is essential for the migration of various cell types that express S1P receptors, such as lymphocytes,
pre-osteoclasts, cancer cells and endothelial cells. To maintain this concentration gradient, plasma S1P concentration must
be at a higher level. However, little is known about the molecular mechanism by which S1P is supplied to extracellular
environments such as blood plasma. Here, we show that SPNS2 functions as an S1P transporter in vascular endothelial cells
but not in erythrocytes and platelets. Moreover, the plasma S1P concentration of SPNS2-deficient mice was reduced to
approximately 60% of wild-type, and SPNS2-deficient mice were lymphopenic. Our results demonstrate that SPNS2 is the
first physiological S1P transporter in mammals and is a key determinant of lymphocyte egress from the thymus.
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Introduction
Sphingosine-1-phosphate (S1P), a bioactive sphingolipid that is
recognized by five G protein-coupled receptors (S1P1–5) and plays
a key role in angiogenesis, bone homeostasis and the immune
system [1,2,3,4,5,6]. Because S1P receptors are located on the cell
surface, S1P, which is produced in the cell from sphingosine by
sphingosine kinases (SPHK1 and SPHK2) and contains a
negatively charged phosphate group, must be exported from the
cells in a carrier-mediated manner. The production of S1P and its
recognition by S1P receptors have been investigated extensively
[7,8,9,10]. However, information on S1P secretion from the cells is
insufficient.
SPHK1 and SPHK2 produce S1P by the phosphorylation of
sphingosine, and S1P is dephosphorylated to regenerate sphin-
gosine by S1P phosphatases (SPPs) and/or extracellular lipid
phosphate phosphatases (LPPs) [10,11,12,13]. S1P is also
degraded by S1P lyase (SPL), leading to the formation of
ethanolamine phosphate and hexadecenal [8,9]. The amount of
S1P is determined by the balance of the activities of the S1P
metabolizing enzymes. The S1P concentration in tissue is
maintained at lower levels due to S1P-degrading activities
[14,15]. In contrast, S1P in plasma exists mainly at higher
concentrations (,mM), in association with high-density lipopro-
tein and albumin [16,17,18]. An exogenous C17-S1P, an S1P
analog, is rapidly degraded in plasma (with a half-life of
approximately 15 minutes), which indicates that there is an
active degradation pathway in plasma; therefore, the high S1P
level in plasma must be maintained by a continuous S1P supply
from S1P-producing cells [19]. Erythrocytes and platelets have
the ability to produce and release S1P into plasma, and
erythrocytes play an important, but not exclusive, role in
maintaining the plasma S1P levels [19,20,21,22,23]. Additionally,
non-hematopoietic sources of plasma S1P, such as vascular
endothelial cells (ECs) or other types of cells, have been proposed
[19,21,24].
In addition to platelets, erythrocytes and ECs, several other
types of cells with the ability to secrete S1P have been identified
[22,23,24,25,26,27]; however the transporter molecules releasing
S1P from the cells into plasma have not yet been identified.
Recently, we described that zebrafish Spns2 (zSpns2) in the yolk
syncytial layer (YSL) functions as an S1P transporter based on an
analysis of the zebrafish mutant ko157 [28]; human and mouse
genomes contain its orthologs. Because YSL is a fish-specific
extra-embryonic tissue, however, the physiological role of SPNS2
in mammals has been unclear. In this report, we report that
SPNS2 functions as an S1P transporter in ECs and is an essential
regulator of lymphocyte egress from the thymus.
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Disruption of mouse SPNS2, an S1P transporter
Human and mouse SPNS2 (hSPNS2 and mSPNS2) have high
sequence identities with zSpns2 (zSpns2 vs. hSPNS2 or mSPNS2 is
72%; hSPNS2 vs. mSPNS2 is 95%). When hSPNS2 or mSPNS2
were expressed in Chinese hamster ovary (CHO) cells expressing
sphingosine kinase (SPHK) 1, the protein localized to the plasma
membrane and exported S1P in a manner similar to zSpns2
(Figure 1) [28,29]. We analyzed SPNS2-deficient mice to examine
the physiological role of mammalian SPNS2.
SPNS2-deficient mice were generated by the disruption of
exon 3–4, which contains the codon encoding Arg200, an amino
acid that is essential for S1P export activity (Figure 1 and Figure
S1) [28]. Spns2 deficiency was confirmed by the absence of Spns2
exons and mRNA (Figure 2). Although SPNS2-deficient mice
were born in the expected Mendelian ratios, they displayed an
eye-open at birth (EOB) phenotype, and approximately 40% of
them succumbed to cryptogenic death at 4 to 5 weeks of age
(Figure S2). Therefore, we used 4-week-old mice for our studies
to avoid analyzing a biased population of SPNS2-deficient mice.
Other than the EOB phenotype, the SPNS2-deficient mice
showed no abnormalities in the cardiovascular system or other
organs, suggesting that there are functional differences between
zebrafish and mammals in the physiological roles of SPNS2 in
cardiogenesis.
SPNS2-deficient mice showed a decrease in S1P plasma
levels
The S1P concentration in the plasma of SPNS2-deficient mice
was approximately 60% of that observed in wild-type mice, while
the S1P concentration in the whole blood fraction (including blood
cells) showed no significant difference (Figure 3A and 3B),
suggesting that SPNS2 plays a significant role in maintaining the
S1P level in plasma by exporting S1P from S1P-producing cells
into the plasma. In various organs (thymus, spleen, lung and
brain), the S1P level showed no significant differences between
wild-type and SPNS2-deficient mice (Figure 3C). Because the S1P
concentration in these organs reflects the amount of intracellular
S1P, we concluded that SPNS2 does not affect the production or
degradation of intracellular S1P.
SPNS2-deficient mice showed a deficiency in thymocyte
egress
One of the most remarkable physiological roles of S1P receptors
is the regulation of lymphocyte egress from lymphoid organs into
the blood [30]. Thus, we examined whether SPNS2 supplies S1P
which is recognized by lymphocyte S1P1 and regulates their
egress. The blood of SPNS2-deficient mice contained significantly
fewer leukocytes (Figure 4A and Table S1), while the numbers of
erythrocytes and platelets were not changed (Figure 4F and 4G,
and Table S1). Within the leukocyte subpopulation, the number of
lymphocytes was drastically decreased, while the numbers of
neutrophils and eosinophils were unchanged (Figure 4B–4E). The
number of monocytes in SPNS2-deficient mice was decreased, but
did not show statistical significance (Figure 4C). Furthermore, the
numbers of circulating CD4
+ and CD8
+ T cells were remarkably
reduced, and the number of circulating B220
+ B cells was
decreased by half compared with wild-type mice (Figure 4H–4J).
These results raised the possibility that the S1P secreted by SPNS2
is essential for lymphocyte circulation. However, there are other
possibilities; for example, the maturation of lymphocytes and/or
the migration of lymphocytes in response to S1P might be
defective in SPNS2-deficient mice.
As shown in Figure 5, T cells examined in the thymus of
SPNS2-deficient mice, and the population of mature T cells (CD4
or CD8 positive; single positive) in the thymus was increased while
that of immature T cells (CD4 and CD8 positive; double positive)
was decreased. To examine the ability of mature thymocytes to
migrate in response to S1P, the amount of S1p1 mRNA in mature
thymocytes was quantified and their migration activity was
measured in a transwell assay. The amount of S1p1 mRNA in
CD4 single positive cells was two to three times higher level than
in CD8 single positive cells, and mature thymocytes of SPNS2-
deficient mice have more S1p1 mRNA than wild-type mice, in
both CD4 and CD8 single positive cells (Figure 5D). Moreover,
CD4 and CD8 single positive cells from SPNS2-deficient mice
showed a high migration activity at a lower S1P dose (1 to 10 nM)
compared to that of wild-type (10 to 100 nM), presumably due to
the increased expression of S1P1 (Figure 5E and 5F). It is possible
that the higher amount of S1p1 mRNA and the increased S1P
sensitivity in single positive cells from SPNS2-deficient mice might
be caused by compensation for the depletion of S1P required for
thymocyte egress. These results indicate that thymocytes of
SPNS2-deficient mice can mature and migrate toward S1P
normally, but they could not emigrate from the thymus into
blood in the absence of SPNS2. Consequently, the number of
circulating T cells in the peripheral blood was dramatically
reduced in SPNS2-deficient mice.
SPNS2 does not function in erythrocytes and platelets
The release of S1P from platelets and erythrocytes has been
compared in detail by ourselves and by other researchers
[22,23,31,32,33,34]. Erythrocytes and platelets are able to
produce and secrete S1P. Erythrocytes predominate among
blood cells, and appear to be the major contributor to plasma
S1P [35]. Therefore, we measured S1P release activity in
erythrocytes isolated from wild-type or SPNS2-deficient mice.
There were no differences in S1P release activity (Figure 6A).
Platelets release S1P in a stimulus-dependent manner, although
the concentration of plasma S1P is not altered in NF-E2-deficient
Figure 1. Mouse SPNS2 exports S1P from the cells. (A) Cellular
localization of mouse SPNS2. CHO-SPHK1 cells expressing EGFP or
mSPNS2-EGFP were observed by confocal fluorescence microscopy
(LSM5 Pascal, Carl Zeiss). (B) The endogenous S1P released from CHO-
SPHK1 cells expressing EGFP, mSPNS2-EGFP or mSPNS2-R200S-EGFP
was separated and quantitated with C17-S1P (internal standard) by
HPLC. The release of endogenous S1P was observed in mSPNS2-EGFP-
transfected cells but not in EGFP-expressing or mSPNS2 (R200S)-EGFP-
expressing cells. The graph shows the average values from three
experiments, with error bars representing the standard error.
doi:10.1371/journal.pone.0038941.g001
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treated mice, which suffer from thrombocytopenia [19,21,23,33].
The thrombin-induced S1P release from platelets isolated from
SPNS2-deficient mice was also comparable to that of wild-type
mice (Figure 6B). The numbers of erythrocytes and platelets in
the blood of wild-type and SPNS2-deficient mice were almost
equivalent (Figure 4F and 4G, and Table S1). Furthermore,
Spns2 transcripts were below the level detectable by quantitative
real-time PCR. These results indicate that SPNS2 is not involved
in S1P production and S1P supply from erythrocytes and
platelets.
SPNS2 is an S1P transporter of vascular ECs
We examined whether vascular ECs utilize SPNS2 for S1P
secretion because it was reported that human umbilical vein ECs
(HUVECs) are able to release S1P into the culture medium [19].
In fact, Spns2 mRNA was detected in ECs of peripheral blood
vessels in the thymus and kidney (Figure S3). The transcription of
Spns2 mRNA was limited to ECs and was not detected at all in
other cells, including blood cells. Although Spns2 mRNA was
detected in the aorta by quantitative real-time PCR, it was not
detected by in situ hybridization in ECs of the aorta or the cava
(Figure 7 and Figure S3K). Because the targeting vector for the
SPNS2-deficient mice was designed to replace Spns2 with the lacZ
gene, tissues from Spns2-heterozygous mice were stained with X-
gal to identify the SPNS2-expressing cells. CD31-positive ECs
were clearly stained with X-gal in the thymus, similar to the in situ
hybridization results. Furthermore, the signals were observed in
ECs of the cava (although not detected by in situ hybridization) but
not in the aorta (Figure 8). These results suggest that there were
enough Spns2 transcripts present in the aorta for detection with
quantitative real-time PCR, but the level of transcript was below
the sensitivity of in situ hybridization and X-gal staining. To
confirm the transcription of Spns2 mRNA in aortic ECs,
quantitative real-time PCR was performed using the mRNAs
from whole aorta and from ECs-depleted aorta. The amount of
Spns2 mRNA was significantly decreased in the ECs-depleted
aorta (Figure 9). The relative transcription of Spns2 mRNA was
higher in the ECs prepared from aorta. When the amount of Spns2
mRNA was normalized to that of Cdh5, an EC marker gene, the
expression level was nearly equivalent, suggesting that the amount
of Spns2 mRNA is dependent on that of ECs (Figure 9). These
results indicate that Spns2 mRNA is transcribed in aortic ECs,
although at a low level.
Mouse aortic ECs (MAECs) were isolated from wild-type and
SPNS2-deficient mice to measure their S1P release activity. Spns2
mRNA was detected in MAECs isolated from wild-type but not
SPNS2-deficient mice (Figure 10A). Cell morphology, the
expression of the EC surface marker CD31 and the mRNA levels
of other EC-specific markers (Nos3, Cdh5 and Icam-2) were similar
in both genotypes, as determined by immunostaining and
quantitative real-time PCR analysis (Figure 10B–10E) [36].
MAECs prepared from wild-type mice showed S1P release
activity, while SPNS2-deficient MAECs completely lost activity
Figure 2. SPNS2-deficient mice. (A) Targeting scheme to generate the Spns2 genomic deletion allele. The exons of the putative coding and
noncoding regions are shown as black and white boxes, respectively. The LacZ-neo
r cassette in the deleted allele is indicated with a white rectangle.
The primers used for genotyping are indicated by arrows. (B) Deletion of mouse Spns2 from the genome was confirmed with PCR using genomic DNA
isolated from Spns2
+/+, Spns2
+/2 and Spns2
2/2 mouse tails. (C) Knock-out of mouse Spns2 was confirmed by conventional RT-PCR using mRNA
isolated from Spns2
+/+ or Spns2
2/2 mouse tissues.
doi:10.1371/journal.pone.0038941.g002
Figure 3. Plasma S1P concentration is decreased in SPNS2-
deficient mice. (A) Concentration of plasma S1P in wild-type (WT,
n=14) and SPNS2-deficient mice (D,n = 9 ) .T h eP-value from
comparisons between WT and D samples is indicated. (B) Concentration
of whole blood S1P in wild-type (WT, n=7) and SPNS2-deficient mice
(D, n=5). (C) S1P contents of mouse tissues. S1P contents of brain,
thymus, lung and spleen from wild-type (WT, n=3) or SPNS2-deficient
(D, n=3) mice were measured by HPLC. C17-S1P was used as the
internal standard. Graphs show the average values from multiple
experiments, with error bars representing the standard error. The P-
values of comparisons between WT and D samples is indicated.
doi:10.1371/journal.pone.0038941.g003
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collected, and leukocytes, leukocyte subpopulations, erythrocytes and platelets were counted using flow cytometry. Bar graphs show the average
values from three experiments. (H–J) Flow cytometric analysis of blood from wild-type (WT, red, n=13) and SPNS2-deficient (D, blue, n=7) mice. CD8
(H), CD4 (I) and B220 (J) were used to detect each cell type. Graphs show the average values from multiple experiments, with error bars representing
the standard error. The P-value of comparisons between WT and D samples is indicated.
doi:10.1371/journal.pone.0038941.g004
Figure 5. Thymocytes of SPNS2-deficient mice can mature and migrate toward S1P. (A and B) Expression profiles for CD4 and CD8.
Thymus-derived CD4
+ and CD8
+ cells from wild-type (A, WT, n=5) and SPNS2-deficient (B, D, n=7) mice were analyzed by flow cytometry. Each plot
is representative of multiple experiments. Numbers show the percent of total lymphocytes, identified by their size. (C) The percentage corresponding
to CD4
+ CD8
+ (DP), CD4
2 CD8
+ (CD8SP) or CD4
+ CD8
2 (CD4SP) populations. (D) Quantitative analysis of S1p1 mRNA in mature thymocytes. CD4 or
CD8 single positive cells were purified from the thymus of wild-type (WT, n=3) or SPNS2-deficient (D, n=5) mice with MACS. The amount of S1p1
mRNA is normalized to that of Hprt. The primers and probes used for PCR are indicated in Table S2. The P-values from comparisons between WT and
D samples are indicated. (E, F) Chemotaxis assays of mature thymocytes of wild-type (WT, n=10) or SPNS2-deficient (D, n=5) mice. The percentage of
input cells of the CD62L
hi and CD4 (E) or CD8 (F) single positive phenotype that migrated toward S1P is shown. open square, wild-type CD4 single
positive; closed square, SPNS2-deficient CD4 single positive; open circle, wild-type CD8 single positive; closed circle, SPNS2-deficient CD8 single
positive. The graphs show the average values from multiple experiments, with error bars representing the standard error.
doi:10.1371/journal.pone.0038941.g005
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MAECs.
We also examined whether SPNS2 functions as an S1P
transporter in human vascular ECs, such as HUVECs and
human pulmonary artery ECs (HPAECs), derived from venous
and arterial endothelia, respectively. When HUVECs or
HPAECs were treated with SPNS2-specific siRNAs, the expres-
sion of SPNS2 mRNA decreased to less than 20% of the control
(Figure 11A and 11B). To investigate the off-target effect of these
siRNAs, the expression of four ABC transporters was examined
because ABCA1, ABCB1, ABCC1 and ABCG2 have been
reported to play a role in S1P release from the cells
[25,27,37,38,39,40]. We confirmed that the expression of these
ABC transporters was not changed between the siRNAs targeting
SPNS2 and the negative control (Figure S4). The amount of
secreted S1P was significantly decreased, while the amount of
intracellular S1P was not altered, in HUVECs or HPAECs
treated with siRNAs targeting SPNS2 (Figure 11C–11F). Because
intracellular S1P should be rigorously controlled by various
sphingolipid metabolizing enzymes such as SPHKs, SPL and
SPPs, the intracellular S1P concentration should show no
significant change regardless of the deletion of S1P secretion
activity. These results indicate that SPNS2 plays a central role in
releasing S1P from ECs in mice and humans.
Discussion
In previous reports, we identified zebrafish Spns2 as a
physiological S1P transporter and revealed that human SPNS2
also transports S1P and its analogs [28,29]. Although there is no
significant difference in enzymatic properties between zebrafish
Spns2 and mammalian SPNS2, YSL is a fish-specific tissue where
zebrafish Spns2 has a physiological function and supplies S1P for
the regulation of myocardial precursor migration [28]. In this
report, we aimed to identify the cells where mammalian SPNS2
functions as an S1P transporter.
Analysis of the cells isolated from SPNS2-deficient mice
demonstrated that mammalian SPNS2 is the S1P transporter
in vascular ECs but not in erythrocytes and platelets. Consistent
with previous reports indicating a predominant role of erythro-
cytes in maintaining the plasma S1P level [22], SPNS2-deficient
mice retain 60% of plasma S1P, which is likely supplied by
unidentified S1P transporter(s) in erythrocytes. Among blood
cells, leukocytes do not release S1P at all, but mast cells can
release S1P [22,26,37]. The contribution of mast cells to plasma
S1P levels, however, does not seem to be significant, due to the
relatively low number of these cells in blood [41,42,43,44].
Therefore, we believe that the decrease in plasma S1P level and
circulating lymphocytes in SPNS2-deficient mice might be
caused by the dysfunction of SPNS2 in vascular ECs, although
the mice used in this study were not vascular endothelial cell-
specific knock-out mice.
Although Spns2 mRNA was detected in peripheral blood vessels
but not in the aorta or the cava by in situ hybridization, transcripts
derived from the Spns2 locus were detected in ECs of the cava but
not the aorta by X-gal staining (Figure 8 and Figure S3). However,
quantitative real-time PCR indicated that Spns2 mRNA was
transcribed in aortic ECs (Figure 9). HUVECs derived from veins
have more Spns2 mRNA than HPAECs derived from the aorta
(Figure 11A and 11B). Taken together, there might be differences
in the expression level of SPNS2 among different regions of blood
vessels, and SPNS2 might have a tendency to be expressed at
higher levels in venous ECs.
To date, four factors concerned with S1P signaling have been
reported to be essential for thymocyte egress: SPHKs for
production of S1P, SPL and LPP3 for maintaining low S1P levels
in the thymus and S1P1 for recognition of the signal
[14,15,21,45,46,47]. SPHKs produce S1P in intracellular spaces,
and S1P1 on thymocytes recognizes S1P in extracellular spaces.
Because high S1P levels cause S1P1 internalization and a defect of
thymocyte egress, extracellular S1P concentration needs to be
strictly regulated. The intracellular and extracellular S1P is
degraded by SPL and LPP3, respectively, resulting in the optimal
extracellular S1P concentration for thymocyte egress. Blood
vessels are the exit for thymocytes from the thymus to the blood.
Thus, vascular ECs may contribute to the S1P supply of the
extracellular space of the thymus. In SPNS2-deficient mice, the
S1P concentration of the extracellular environment around
peripheral vascular endothelial cells in the thymus may be
decreased, and mature thymocytes may not recognize S1P to
exit, although the total S1P concentration of the thymus was not
changed (Figure 3). We proposed that SPNS2 is a novel fifth factor
involved in thymocyte egress.
Figure 6. SPNS2 does not function in erythrocytes and
platelets. (A) Time-dependent S1P release from erythrocytes. Erythro-
cytes from wild-type (closed squares, n=3) and SPNS2-deficient mice
(open circles, n=4) were incubated with [
3H]sphingosine at 37 uC, and
[
3H]S1P exported into the medium was measured at the indicated
times. S1P release is shown as a percentage: (amount of supernatant)/
(total amount). (B) Thrombin induced S1P release from platelets.
Platelets from wild-type (WT, n=4) and SPNS2-deficient mice (D,n=4 )
were incubated in the presence or absence of thrombin, and S1P
released into the medium was measured by UPLC-MS/MS. The graphs
show the average values from multiple experiments, with error bars
representing the standard error.
doi:10.1371/journal.pone.0038941.g006
Figure 7. Tissue distribution of Spns2 mRNAs. Quantitative real-
time PCR was performed with first strand cDNA synthesized from
mRNAs of various mouse tissues. The amount of Spns2 mRNA in each
tissue is shown relative to that of Hprt. The primers and probes used for
PCR are given in Table S2. The graph shows the average values from
four experiments, with error bars representing the standard error.
doi:10.1371/journal.pone.0038941.g007
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EOB phenotype, suggesting that SPNS2 also functions in cells
other than the vascular ECs. The EOB phenotype seems to be
due to the dysfunction of the migration of eyelid cells at the
embryonic stage, as shown in c-Jun- or LGR4-deficient mice
[48,49,50]. A correlation between any S1P receptors function
and eyelid migration has not been reported. S1P signaling
through receptors participates in the migration of myocardial
precursors, osteoclast precursors and various types of cells
[5,28,51,52]. Although extensive experimentation is necessary
to elucidate the physiological roles of S1P, it is possible that the
contribution of S1P signaling to eyelid cell migration could be
demonstrated by further analysis of the SPNS2-deficient mice.
Furthermore, analysis of both secretion and signal-receiving
processes would be useful for elucidating the complete picture of
S1P signaling.
Using SPNS2-deficient mice, we have demonstrated that
SPNS2 regulates plasma S1P levels and is indispensable for
thymocyte egress. S1P signaling is essential for the migration of
various cell types such as lymphocytes, preosteoclasts and ECs.
These results, along with our previous observations that zebrafish
Spns2 mutants are defective in myocardial precursor migration
[28], indicate that SPNS2 is a common regulator of the migration
of cells expressing S1P receptor.
During the reviewing process of this manuscript, it was reported
(Fukuhara S. et. al. J. Clin. Invest. 122, 1416–1426 (2012) ) that
SPNS2 expressed in endothelial cells regulates lymphocyte
trafficking in mice.
Materials and Methods
Reagents
Antibodies against CD31 were from BD Biosciences (MEC
13.3) and Spring Bioscience (polyclonal antibody). Antibodies
against CD8 (53-6.7), CD4 (RM4-5), B220 (RA3-6B2) and CD62L
(MEL-14) were from BioLegend, Inc. Bovine serum albumin (fatty
Figure 8. Immunohistochemical analysis of thymus. (A–C), aorta (D) and cava (E) sections from SPNS2-heterozygous mice, stained with X-gal
(blue) and immunostained with CD31 antibody (brown). a, aorta; b, blood vessel; c, cava, bar, 50 mm.
doi:10.1371/journal.pone.0038941.g008
Figure 9. Spns2 mRNA is expressed in aortic ECs. Quantitative real-time PCR was performed with first strand cDNA synthesized from mRNAs of
the aorta. The relative amounts of Spns2 (A and D), Cdh5 (B) and Myl9 (C) mRNA were measured using total RNA prepared from mouse whole aorta
(aorta), aorta where ECs were removed by the collagenase-treatment (aorta D EC) or ECs which were recovered from that aorta (EC). Cdh5 and Myl9
were used as ECs and smooth muscle cell marker genes, respectively. The primers and probes used for PCR are indicated in Table S2. The graph
shows the average values from four experiments, with error bars representing the standard error.
doi:10.1371/journal.pone.0038941.g009
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S1P were from Avanti.
Mice
SPNS2-deficient mice were generated by Deltagen, Inc. (San
Mateo, CA, USA) by replacing part of exon 6 and exon 7 of the
mouse Spns2 gene with a lacZ-Neomycin cassette (Figure 2). This
deleted region contains the codon encoding the Arg200 that is
essential for the S1P export activity of SPNS2 (Figure 1 and 2).
SPNS2-deficient mice were backcrossed onto the C57BL/6
background for ten generations to create a congenic strain.
Genotyping of SPNS2-deficient mice was performed by PCR
against genomic DNA isolated from the tail of each mouse. PCR
conditions and primers were as follows: 30 cycles of denature
(96uC, 10 sec), annealing (60uC, 30 sec), and extension (68uC,
90 sec) using SPNS2-F, GGTCCTCCA-
GAATTCTCTGTTCTCC; Neo-F, GGGCCAGCT-
CATTCCTCCCACTCAT and SPNS2-R, TTGTGGCAGTT-
CACACTTACCTGCC. Wild-type mice used as control in this
study were littermates of the SPNS2-deficient mice. Mice were
housed under conventional conditions at the animal care room at
ISIR, Osaka University. All experimental procedures followed
the regulations of the Institutional Animal Care and Use
Committee of ISIR, Osaka University (approval # 19-02-1).
MAECs
MAECs were isolated according to the methods of Kobayashi
et al. with some modifications [36]. Briefly, the mouse aorta was
dissected out from the aortic arch to the abdominal aorta and
immersed in 20% FBS-DMEM containing 100 units/ml heparin,
100 units/ml penicillin-G and 100 mg/ml streptomycin. A 24-
gauge cannula was inserted into the proximal portion and the
distal end was closed with a silk thread and filled with collagenase
type II solution. After incubation for 45 min at 37uC, ECs were
removed from the aorta by flushing with 2 ml of 20% FBS-
DMEM, resuspended with 20% FBS-DMEM and cultured in a
24-well collagen type I-coated plate. To remove smooth muscle
cells, after 2 hr of incubation at 37uC, the ECs were washed with
warmed 20% FBS-DMEM and cultured in medium G until
confluent.
Human vascular ECs
HUVECs and HPAECs were purchased from Cell Applica-
tions, Inc. These cells were cultured following the manufacturer’s
instructions.
Flow cytometry
Cell suspensions from the thymus were prepared by mincing
organs in RPMI 1640 medium and then passing the cells through
a nylon mesh. Erythrocytes were removed from blood samples by
incubation in Lysis buffer (BD Biosciences). Isolated cells were
labeled with the antibodies and analyzed using Guava easyCyte
8HT.
Separation of single positive thymocytes
CD4 or CD8 single positive cells were purified from the thymus
of mice by negative and positive selection using specific MACS
microbeads conjugated to anti-mouse CD4 or CD8 antibodies
(Miltenyi Biotech). Briefly, for the separation of CD4 single
positive cells, thymus cell suspensions were labeled with CD8
MicroBeads and then passed over an LD column. The negatively
selected cells were treated with CD4 MicroBeads and then passed
over an LS column. CD4 single positive cells were enriched in the
positively selected cell fraction. For the separation of CD8 single
positive cells, the opposite of the selection protocol for the CD4
single positive cell selection was performed; CD4-positive cells
were depleted and CD8-positive cells were collected. The
separated cell populations were analyzed by flow cytometry, and
the purity was more than 80%.
Chemotaxis assays
Chemotaxis assays were performed as described previously,
with slight modifications [45]. Briefly, cell suspensions from the
Figure 10. SPNS2 is an S1P transporter of vascular EC. (A–D) The relative amount of the indicated mRNAs in MAECs isolated from wild-type
(WT) and SPNS2-deficient mice (D). The amount of each mRNA was normalized to that of Hprt. (E) CD31 expression by MAECs was detected by
immunostaining with CD31 antibody. (F) The amount of endogenous S1P released from MAECs. The cells were incubated with 1% BSA for 4 hr at 37
uC, and the released S1P was measured by UPLC-MS/MS. The graphs show the average values from three experiments, with error bars representing
the standard error. N.D., not detected.
doi:10.1371/journal.pone.0038941.g010
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containing various concentration of S1P was added to the lower
chamber of 5 mm-transwells (Corning). After 3 hr of incubation at
37uC, the cells collected from the upper and lower chambers were
labeled with the anti-CD4, anti-CD8 and anti-CD62L antibodies
and analyzed by flow cytometry.
Measurement of S1P release from mouse erythrocytes
Mice were anesthetized, and blood was collected from their
hearts using an acid citrate-dextrose solution (ACD) as an
anticoagulant. Erythrocytes were prepared by centrifugation at
1006g for 15 min at room temperature and washed twice with a
mixture of buffer A (20 mM HEPES-NaOH (pH 7.4), 3.3 mM
NaH2PO4, 2.9 mM KCl, 1 mM MgCl2, 138 mM NaCl and
1 mg/ml glucose) containing 1% BSA, followed by immediate
resuspension in the same buffer. S1P release from erythrocytes
was measured as reported previously, with slight modifications
[31]. The erythrocyte suspensions (180 ml, 1610
7 erythrocytes/
ml) in buffer A containing 1% BSA were preincubated for 5 min
at 37uC. Assay buffer containing 0.2 mM[
3H]sphingosine
(40 nCi/10 ml) in buffer A and 1% BSA was then added to
each suspension (final concentration of sphingosine, 10 nM) and
incubated at 37uC. After an indicated incubation period,
erythrocytes and the assay buffer were separated by centrifuga-
tion at 12,0006g for 5 sec at 4uC. Lipids were extracted from the
supernatant and erythrocytes and developed by HPTLC (Merck)
in butanol/acetic acid/water (3:1:1 v/v). Radioactive bands were
quantified with a FLA-3000G Bioimaging Analyzer (Fujifilm).
Measurement of S1P release from platelets
Mouse blood was collected as described above, and then
platelet-rich plasma (PRP) was obtained by centrifugation at
1006g for 15 min at room temperature. Platelets were prepared
by centrifugation of PRP at 1,0006g for 15 min and washed with
buffer A containing 1% BSA, followed by immediate resuspension
in the same buffer. S1P release from platelets was measured as
reported previously, with slight modifications [33,34]. First, 190 ml
of platelet suspensions (1610
8 platelets/ml) in buffer A containing
1% BSA were preincubated for 10 min at 37uC. Then, 10 mlo f
thrombin (final concentration, 5 units/ml) was added to the
mixture, followed by incubation for 10 min. After incubation, the
platelets and the medium were separated by centrifugation at
12,0006g for 5 sec at 4uC. An equal volume of methanol was
added to the supernatant, samples were precipitated by centrifu-
gation at 12,0006g for 5 min at 4uC, and the resulting supernatant
was applied to a Cosmospin filter G and analyzed by UPLC-MS/
MS.
Measurement of S1P release from ECs
MAECs were cultured in a 24-well collagen type I-coated plate
until confluent, when the number of cells was approximately
1610
5 cells/well. HUVECs and HPAECs were cultured in a 6-
well plate for 2 days after the siRNA transfection, when the
number of cells was approximately 2610
5 cells/well. The medium
of the cultured ECs was replaced with releasing medium
(endothelial cell serum-free defined medium (Cell Applications)
with 1% BSA, 10 mM sodium glycerophosphate, 5 mM sodium
fluoride, 1 mM semicarbazide and 20 mM HEPES-KOH
(pH 7.4)). After 4 hr of incubation at 37uC, 200 ml aliquots of
releasing medium were collected, and the cells were removed by
centrifugation at 12,0006g for 5 min at 4uC. An equal volume of
methanol was added to the supernatant, the samples were
precipitated by centrifugation at 12,0006g for 5 min at 4uC and
the resulting supernatant was applied to a Cosmospin filter G and
analyzed by UPLC-MS/MS.
S1P measurement by HPLC
Mouse plasma, organs and cells were assessed for o-
phthalaldehyde (OPA) modification followed by HPLC analysis
according to a modified protocol from Min et al. [53]. Plasma
was prepared from whole blood by centrifugation at 2,0006g for
15 min at room temperature. C17-S1P (30 pmol) was added to
each 100 ml aliquot of the sample as an internal standard and
subjected to lipid extraction in alkaline chloroform conditions.
Organs (thymus, spleen, lung and brain) were homogenized in
PBS, and C17-S1P (30 pmol) was added to each sample. Total
lipid in the organs was extracted using the Bligh-Dyer method
[54] and subjected to lipid extraction in alkaline chloroform
conditions. The cultured cells were washed with PBS twice,
scraped and homogenized. C17-S1P (30 pmol) was added to each
100 ml aliquot of sample and subjected to lipid extraction in
alkaline chloroform conditions. Extracted S1P was dephosphor-
ylated with calf intestinal alkaline phosphatase (30 units) for
90 min at 37uC. The resulting sphingosine was extracted with
Figure 11. SPNS2 releases S1P from human vascular ECs.
HUVECs and HPAECs were treated with two siRNAs targeting SPNS2
mRNA or with a negative control siRNA. (A and B) Relative amount of
SPNS2 mRNA in cells treated with siRNA. Total RNA was isolated, and
SPNS2 and GAPDH mRNA levels were determined by quantitative real-
time PCR. The amount of SPNS2 mRNA is normalized to GAPDH mRNA.
(C and D) Intracellular S1P. (E and F) The cells were incubated with 1%
BSA for 4 hr at 37 uC, and the released S1P was measured by UPLC-MS/
MS. The cells were collected, and the intracellular S1P content was
measured by HPLC. C17-S1P was used as the internal standard. The
graphs show the average values from three (C and E) or four (A, B, D
and F) experiments, with error bars representing the standard error.
*P,0.005 compared to ‘control’.
doi:10.1371/journal.pone.0038941.g011
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modification was performed for 1 hr at room temperature. After
centrifugation of the samples, a 15 ml aliquot of the sample
(135 ml) was analyzed by HPLC (Hitachi) with a Cosmosil 5C
18-AR-II column (Nacalai tesque).
S1P measurement by UPLC-MS/MS
The endogenous S1P secreted from ECs and platelets was
measured by UPLC-MS/MS. The UPLC-MS/MS analysis was
performed with an Acquity ultra-performance liquid chromatog-
raphy liquid handling system and a Quattro Premier XE triple
quadrupole mass spectrometer controlled by MassLynx (version
4.1) MS and chromatography manager software (Waters). The
separation was performed on an Acquity BEH C18 analytical
column (2.1 by 100 mm; particle size, 1.7 mm, Waters) using a
mobile phase consisting of eluent A (water/formic acid (100:0.1 v/
v)) and eluent B (acetonitrile/tetrahydrofuran/formic acid
(50:50:0.1 v/v)). The gradient was as follows: From t=0 to
0.5 min A/B 50:50, followed from t=0.5 to 3 min by a linear
gradient from A/B 50:50 to 0:100, then from t=3 to 7 min A/B
0:100, t=7 to 7.1 min by a linear gradient from A/B 0:100 to
50:50 and finally from t=7.1 to 12 min A/B 50:50 at a flow rate
of 0.300 ml/min. A Quattro premier mass spectrometer was used
in the positive ion electrospray mode with a source temperature of
120uC and a desolvation temperature of 350uC. Nitrogen was
used as the nebulizing, auxiliary and desolvation gas, while argon
was used as the collision gas. S1P was monitored utilizing a
Multiple Reaction Monitor (MRM) at m/z 380.31 to m/z 264.2.
The cone voltage and collision energy were set at 24 V and 14 eV,
respectively.
Gene knock-down with siRNAs
At 24 hr before transfection, cells were plated in 6-well plates at
a density that would allow them to be 50% confluent at the time of
transfection. Cells were transfected with 10 nM siRNA to silence
human SPNS2 or negative control siRNA (Ambion) using
Lipofectamine RNAiMAX according to the manufacturer’s
instructions. Experiments were performed at 48 hr after the
transfection of siRNA.
Immunostaining
MAECs were seeded on collagen type I-coated glass and
confluent cells were fixed with cold methanol for 10 min. After
incubation with blocking buffer (PBS containing 1% BSA and 1%
FBS) for 30 min at room temperature, the antibody against CD31
(MEC 13.3) conjugated with FITC was incubated with the cells for
3 hr at room temperature. After three washes with washing buffer
(PBS containing 0.1% BSA and 0.1% FBS), the cells were
mounted with GEL/MOUNT and photographed with BIOR-
EVO (Keyence).
X-gal staining
Tissues from SPNS2-heterozygous mice were fixed overnight in
0.2% paraformaldehyde in 100 mM PIPES (pH 6.9) containing
2 mM MgCl2 and 5 mM EGTA, and cryoprotected in 30%
sucrose containing 2 mM MgCl2. Subsequently, they were frozen
in OCT compound and sectioned at 6–7 mm on a cryostat. The
slides were rehydrated with PBS, rinsed with 100 mM phosphate
buffer (pH 7.3) containing 2 mM MgCl2, 0.02% Nonidet P-40
and 0.01% sodium deoxycholate at 4 uC, and then stained with
100 mM phosphate buffer (pH 7.3) containing 2 mM MgCl2,
0.02% Nonidet P-40, 0.01% sodium deoxycholate, 5 mM
potassium ferricyanide, 5 mM potassium ferrocyanide, 0.4 mM
Tris-HCl (pH 7.3) and 20 mg/mL X-gal at 37 uC in the dark. The
slides were then permeabilized with 0.5% Triton X-100 in PBS,
treated with 3% H2O2 in methanol for elimination of intrinsic
peroxidase activity, and stained with CD31 antibody (Spring
Bioscience). Histofine simplestain (Nichirei) and the Liquid DAB+
Substrate chromogen System (Dako) were used for the detection of
the primary antibody.
RT-PCR
Total RNA was extracted from cells using the PureLink RNA
Mini Kit (Invitrogen) according to the manufacturer’s instructions.
The concentration and purity of the RNA were determined
spectrophotometrically by measuring the absorbance at 260 nm
and 280 nm using a NanoDrop (Thermo). The mRNA was
reverse transcribed using the SuperScript VILO cDNA Synthesis
Kit (Invitrogen). We also used first-strand cDNA from C57BL/6J
mouse tissues obtained from Genostaff Co., Ltd. for RT-PCR and
quantitative real-time PCR.
in situ hybridization
Paraffin embedded blocks and sections of mouse thymus, kidney
and small intestine for in situ hybridization (ISH) were obtained
from Genostaff Co., Ltd. Tissues were dissected, fixed with Tissue
Fixative (Genostaff), embedded in paraffin using their proprietary
procedures and sectioned at 5 mm. For ISH, tissue sections were
de-waxed with xylene and rehydrated using an ethanol series and
PBS. The sections were fixed with 4% para-formaldehyde in PBS
for 15 min and then washed with PBS. The sections were treated
with 30 mg/ml Proteinase K in PBS for 30 min at 37uC, washed
with PBS, re-fixed with 4% para-formaldehyde in PBS, washed
again with PBS, and placed in 0.2 N HCl for 10 min. After being
washed with PBS, the sections were acetylated by incubation in
0.1 M tri-ethanolamine-HCl (pH 8.0) with 0.25% acetic anhy-
dride for 10 min. After being washed with PBS, the sections were
dehydrated through an ethanol series. Hybridization was per-
formed with probes at 300 ng/ml in Probe Diluent-1 (Genostaff)
for 16 hr at 60uC. After hybridization, the sections were washed in
56HybriWash (Genostaff), equivalent to 56SSC, for 20 min at
50uC and then in 50% formamide and 26HybriWash for 20 min
at 50uC, followed by RNase treatment in 50 mg/ml RNase A in
10 mM Tris-HCl (pH 8.0), 1 M NaCl and 1 mM EDTA for
30 min at 37uC. The sections were then washed twice with 26
HybriWash for 20 min at 50uC, twice with 0.26HybriWash for
20 min at 50uC, and once with 0.1% Tween 20 in TBS (TBS-T).
After treatment with 0.5% blocking reagent (Roche) in TBS-T for
30 min, the sections were incubated with anti-DIG AP conjugate
diluted 1:1000 in TBS-T for 2 hr at room temperature. The
sections were washed twice with TBS-T and then incubated in
100 mM NaCl, 50 mM MgCl2, 0.1% Tween 20, and 100 mM
Tris-HCl (pH 9.5). Staining reactions were performed with NBT/
BCIP solution overnight and then washed with PBS. The sections
were counterstained with Kernechtrot stain solution and mounted
with CC/Mount.
Quantitative real-time PCR
Quantitative real-time PCR was performed using the first strand
cDNA as described above with the FastStart Master Mix with
ROX (Roche Applied Science) using an ABI PRISM 7000
sequence detection system. Primers and probes used for quanti-
tative real-time PCR are listed in Table S2.
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To analyze statistical significance, we used an unpaired two-
tailed Student’s t-test. We considered P-values,0.05 to be
significant.
Supporting Information
Figure S1 Nucleotide and amino acid sequence of
mouse SPNS2. Nucleotide sequences of mouse Spns2 (GenBank
accession number NM_153060) are shown together with the
predicted amino acid sequences. The deleted region in the
SPNS2-deficient mice is indicated in the blue box. The nucleotide
sequence used for the in situ hybridization probe is shown with a
red box. The positions of the primers used for RT-PCR are
indicated with arrows. The positions of the intron are indicated
with arrow heads. Amino acid residues conserved between mouse
and human SPNS2 are indicated with bold letters.
(TIFF)
Figure S2 Phenotype of SPNS2-deficient mice. (A)
SPNS2-deficient mice show an eye-open at birth phenotype.
Arrowheads indicate the eyes of SPNS2-deficient mice that are
opened. (B) Body weight of mice at 4 weeks old. Body weight in
wild-type (+/+, male n = 30, female n=25), heterozygous (+/2,
male n=39, female n=51) and SPNS2-deficient (2/2, male
n=28, female n=23) mice was measured at 4 weeks. Error bars
represent standard error. *P,0.005 compared to ‘WT’. (C)
Survival rate of mice. Survival rate in wild-type (+/+, n=55),
heterozygous (+/2, n=98) and SPNS2-deficient (2/2, n=39)
mice is indicated as the percent of total natal number.
(TIFF)
Figure S3 RNA in situ hybridization in mouse tissue
sections. Serial sections of thymus were used for the detection of
Spns2 mRNA with an antisense Spns2 probe (A) and ECs with a
CD31 antibody (B). Serial sections of mouse thymus (C, E and D,
F) were treated with antisense (C and D) or sense (E and F) Spns2
probe. The region used for the probe is indicated in Supplemental
Figure 1. Thymus sections from SPNS-deficient mice were treated
with antisense Spns2 probe (G) or ß-actin probe (H). Serial sections
of mouse kidney were treated with antisense (I) or sense (J) Spns2
probe. Cells in which a positive signal was detected with the
antisense probe are indicated by arrowheads. Serial sections of
mouse aorta were treated with antisense Spns2 probe (K) or ß–actin
probe (L). a, aorta, b, blood vessel, c, cava, Bar, 50 mm.
(TIFF)
Figure S4 Relative amount of ABC transporter mRNA in
human ECs after siRNA-treatment. HUVECs (A) and
HPAECs (B) were transfected with two siRNAs targeting SPNS2
mRNA (siRNA-1 or 2) or a negative control siRNA (control).
Total RNA was isolated, and mRNA levels of ABCA1, ABCB1,
ABCC1, ABCG2 and GAPDH were determined by quantitative real
time PCR as described in Methods. Amount of mRNA of each
ABC transporter is normalized with that of GAPDH. Graphs show
the average values from four experiments, with error bars
representing standard error.
(TIFF)
Table S1 Results of blood analysis of wild-type and
SPNS2-deficient mice. Blood was isolated from 4–5 weeks old
wild-type (WT) and SPNS2-defecient (KO) mice and used for
analysis of indicated blood parameters. MCV, MCH and MCHC
are Mean Corpuscular Volume, Mean Corpuscular Hemoglobin
and Mean Corpuscular Hemoglobin Concentration, respectively.
(DOCX)
Table S2 Primers and probes used for quantitative real
time PCR. Amount of the transcript for each gene (gene) was
determined by the Quantitative real-time PCR using Forward
primer, Reverse primer and indicated number of TaqMan probe
(probe) in Roche Universal Probe Library Set.
(DOCX)
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